A panel of cardiologists discuss the key updates from the 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease risk.
Healio partners with CMHC for annual congress healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
The Evolving Narrative of HDL-C: Contemporary Insights on Quality vs. Quantity for Targeting Cardio Protection healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
New data from the phase 2 ROSE2 trial is providing insight into the safety and tolerability, as well as LDL-lowering effects, of obicetrapib as an adjunct to high-intensity statin therapy as a monotherapy and in combination with ezetimibe.